Four Rings Pharmaceuticals (00460.HK) releases its interim results, with a net profit attributable to shareholders of 103 million yuan, turning losses into gains year-on-year.

The Zhongtong Financial APP news, Four Rings Medicine (00460.HK) released its mid-term performance for 2025, with a revenue of 1.146 billion yuan (RMB, same below), an increase of 20.69% year-on-year; net profit attributable to shareholders was 103 million yuan, compared to a net loss attributable to shareholders of 33.424 million yuan in the same period last year, turning a loss into a profit year-on-year; basic earnings per share were 1.11 cents; planning to distribute an interim cash dividend of 0.99 cents per share.